Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Astrazeneca (AZN) reported $15.38 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 6.4%. EPS of $2.63 for the same period compares to $2.18 a year ago.

The reported revenue represents a surprise of +0.48% over the Zacks Consensus Estimate of $15.31 billion. With the consensus EPS estimate being $2.50, the EPS surprise was +5.2%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• BioPharmaceuticals- R&I- Symbicort- U.S.: $254 million versus $325.13 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -20.4% change.
• BioPharmaceuticals- R&I- Pulmicort- U.S.: $2 million compared to the $1.02 million average estimate based on two analysts. The reported number represents a change of +100% year over year.
• BioPharmaceuticals- CVRM- Crestor- U.S.: $10 million versus $10.38 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -16.7% change.
• Oncology- Tagrisso- U.S.: $845 million versus the two-analyst average estimate of $840.91 million. The reported number represents a year-over-year change of +11%.
• BioPharmaceuticals- R&I- Symbicort- World: $671 million versus $707.32 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.2% change.
• Alliance Revenue- Total: $874 million versus $875.65 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +33.6% change.
• BioPharmaceuticals- CVRM- Crestor- World: $331 million compared to the $352.65 million average estimate based on two analysts. The reported number represents a change of +3.8% year over year.
• BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World: $157 million versus $152.9 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.1% change.
• Oncology- Tagrisso- World: $1.94 billion versus the two-analyst average estimate of $2.01 billion. The reported number represents a year-over-year change of +7.2%.
• BioPharmaceuticals- R&I- Fasenra- World: $570 million compared to the $563.06 million average estimate based on two analysts. The reported number represents a change of +13.6% year over year.
• BioPharmaceuticals- CVRM- Brilinta- World: $80 million versus the two-analyst average estimate of $93.8 million. The reported number represents a year-over-year change of -62.8%.
• BioPharmaceuticals- CVRM- Farxiga- World: $1.8 billion versus $1.8 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -16.1% change.

View all Key Company Metrics for Astrazeneca here>>>

Shares of Astrazeneca have returned -10.2% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research